Business Context and Reporting Period
InterCure Ltd., a foreign private issuer based in Herzliya, Israel, filed Form 6-K on February 19, 2026. The filing reports on preliminary estimated financial results for the full fiscal year 2025.
Key Financial Metrics
- Revenue: Preliminary estimated 2025 revenue of NIS 265 million.
- Profitability: The company reported positive Adjusted EBITDA for the period.
- Liquidity: Cash balance of NIS 43 million as of the reporting date.
- Debt and Margins: The filing text does not provide specific values for debt levels, gross margins, or net income.
Material Changes
The filing text does not provide comparative data for the prior period (2024) or specific percentage changes in revenue, profit, or cash flow versus the prior year.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the preliminary 2025 estimates. The filing does not contain specific forward-looking guidance for 2026, detailed risk factors, or disclosures regarding contingencies and unusual items beyond the press release summary.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed breakdowns of Adjusted EBITDA and cash flow components.
- Confirm the exact currency exchange rate used for NIS to USD conversion if applicable for international investors.
- Review the upcoming audited annual report (Form 20-F) for finalized figures and debt covenant compliance.
- Investigate the drivers behind the positive Adjusted EBITDA to understand operational efficiency improvements.